|
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2921-2922.
 Previous Article | Table of Contents | Next Article 
CORRESPONDENCE
To the editor:
Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is a prothrombotic immune-mediated adverse drug reaction that usually begins 5 or more days after starting heparin.1 One randomized clinical trial reported a significant difference in HIT between unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in postoperative orthopedic patients.2 To corroborate that LMWH is safer than UFH in this patient population, we performed a "before-after" prospective cohort study in which 231 consecutive patients over a 9-month period received UFH (Liquemin [Roche, Basel, Switzerland], 5000 IU 3 times/day subcutaneously) following hip or knee replacement. During the subsequent 12-month period, 271 patients received LMWH (enoxaparin [Clexane; Sanofi-Aventis, Frankfurt, Germany], 40 mg/d subcutaneously). Both anticoagulants were started the night before surgery. The primary study end point was HIT, defined a priori as a positive test for HIT antibodies (platelet activation assay3) plus a 30% or greater fall in the platelet count between postoperative days 4 to 16, and/or symptomatic, objectively documented thrombosis (venous or arterial). We predefined thrombotic events occurring between days 5 to 16 as potentially HIT related. Routine testing for HIT antibodies was also performed in most patients at end of study (day 16). Stored sera were also tested posthoc for anti-PF4/polyanion antibodies (GTI, Brookfield, WI).4 Clinical events were adjudicated by 2 investigators by consensus. The study was approved by the ethics committee of the University of Greifswald. The patients we report overlap somewhat with those included in a previous publication5 reflecting the participating surgeons' perspective; however, that report included an additional 130 nonstudy patients, used a different definition of HIT (> 50% platelet count fall), and did not report systematic serologic investigations.
We found a higher frequency of HIT in patients who received UFH (5.2%; 95% confidence interval [CI], 2.7%-8.9%), compared with LMWH (0%; 95% CI, 0.0%-1.4%); P < .001 (Table 1). In addition to the 6 patients who had thrombosis associated with HIT, 5 patients had thrombosis without HIT (3 in the UFH group, 2 in the LMWH group). Thus, total thrombosis (both HIT and non-HIT) was significantly more frequent in UFH-treated patients (Table 1). Two other findings deserve comment. First, among the 431 patients undergoing serologic testing who did not develop HIT manifesting as a platelet count fall, there was a strong association between symptomatic thrombosis after day 4 and a positive platelet activation test for HIT antibodies: 3 (50.0%) of 6 patients with thrombosis tested antibody positive, compared with 26 (6.1%) of 425 patients without thrombosis (odds ratio [OR], 15.3 [95% CI, 2.94-25.23]; P = .005). This supports previous suggestions6 that formation of platelet-activating HIT antibodies can be associated with thrombosis even in the absence of a significant platelet count fall. Second, among the 87.7% of study patients who underwent serologic testing for HIT antibodies, there was approximately a 60% lower seroconversion rate with LMWH compared with UFH (55.6% and 64.7% by the platelet activation assay and immunoassay, respectively). Nevertheless, despite this moderate reduction in frequency of HIT antibody formation, there was complete avoidance of clinical HIT using LMWH (0 versus 12 cases). This underscores the importance of considering HIT to be a largely preventable adverse drug reaction, at least in postorthopedic surgery patients.
View this table:
[in this window]
[in a new window]
|
Table 1.. Frequency of HIT, thrombosis (HIT, non-HIT associated, total), and HIT antibodies in before-after prospective cohort study comparing UFH and LMWH after orthopedic surgery
|
|
Andreas Greinacher,
Petra Eichler,
Theresia Lietz, and
Theodore E. Warkentin
Correspondence: Andreas Greinacher, Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Sauerbruchstraße, 17489 Greifswald, Germany; e-mail: greinach{at}uni-greifswald.de
References
- Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344: 1286-1292.[Abstract/Free Full Text]
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332: 1330-1335.[Abstract/Free Full Text]
- Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991;66: 734-736.[Medline]
[Order article via Infotrieve]
- Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138: 22-31.[CrossRef][Medline]
[Order article via Infotrieve]
- Ganzer D, Gutezeit A, Mayer G. Gefahrenpotentiale in der medikamentösen thromboseprophylaxe-niedermolekuläre heparine versus standardheparin. Z Orthop Ihre Grenzgeb. 1999;137: 457-461.[Medline]
[Order article via Infotrieve]
- Hach-Wunderle V, Kainer K, Krug B, Mueller-Berghaus G, Poetzsch B. Heparin-associated thrombosis despite normal platelet counts [letter]. Lancet 1994;344: 469-470.[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff
Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
340S - 380S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher
So, Does Low-Molecular-Weight Heparin Cause Less Heparin-Induced Thrombocytopenia Than Unfractionated Heparin or Not?
Chest,
October 1, 2007;
132(4):
1108 - 1110.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Levy, K. A. Tanaka, and M. J. Hursting
Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia
Anesth. Analg.,
September 1, 2007;
105(3):
570 - 582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Calderon-Gerstein, G. Famularo, G. Minisola, C. De Simone, and C. W. Francis
Prophylaxis for Thromboembolism in Hospitalized Medical Patients
N. Engl. J. Med.,
July 19, 2007;
357(3):
304 - 306.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin and J. W. Eikelboom
Who Is (Still) Getting HIT?
Chest,
June 1, 2007;
131(6):
1620 - 1622.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Smythe, J. M. Koerber, and J. C. Mattson
The Incidence of Recognized Heparin-Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital
Chest,
June 1, 2007;
131(6):
1644 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. King, A. B. Holley, J. L. Jackson, A. F. Shorr, and L. K. Moores
Twice vs Three Times Daily Heparin Dosing for Thromboembolism Prophylaxis in the General Medical Population: A Metaanalysis
Chest,
February 1, 2007;
131(2):
507 - 516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin and M. A. Crowther
When is HIT Really HIT?
Ann. Thorac. Surg.,
January 1, 2007;
83(1):
21 - 23.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Cooney
Heparin-induced thrombocytopenia: advances in diagnosis and treatment.
Crit. Care Nurse,
December 1, 2006;
26(6):
30 - 36.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin, J.-A. I. Sheppard, C. S. Sigouin, T. Kohlmann, P. Eichler, and A. Greinacher
Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia
Blood,
November 1, 2006;
108(9):
2937 - 2941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schenk, A. El-Banayosy, W. Prohaska, L. Arusoglu, M. Morshuis, W. Koester-Eiserfunke, L. Kizner, E. Murray, P. Eichler, R. Koerfer, et al.
Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support
J. Thorac. Cardiovasc. Surg.,
June 1, 2006;
131(6):
1373 - 1381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin, R. J. Cook, V. J. Marder, J.-A. I. Sheppard, J. C. Moore, B. I. Eriksson, A. Greinacher, and J. G. Kelton
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
Blood,
December 1, 2005;
106(12):
3791 - 3796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin
HIT as a preventable disease?
Blood,
October 15, 2005;
106(8):
2600 - 2600.
[Full Text]
[PDF]
|
|
|
| |
